



## STATE-OF-THE-ART SPEAKER

Nancy Ascher, MD, PhD



University of California San Francisco  
Professor of Surgery  
Division of Transplant Surgery  
Isis Distinguished Professor in Transplantation

**PRESENTATION TITLE:** United States' Role in Global Transplantation

*Paul I. Terasaki State-of-the-Art Lecture*

***Sponsored by the Terasaki Innovation Center***

**Sunday, June 5, 2022**

**11:30 am - 12:00 pm ET**

Dr. Nancy Ascher has devoted her career to organ transplantation and transplant research. She is the first woman to have performed a liver transplant and has inspired many women in the medical field, especially in transplantation.

She completed her undergraduate and medical education at the University of Michigan, Ann Arbor; and completed her general surgery residency and clinical transplantation fellowship at the University of Minnesota, where she later joined the faculty and became Clinical Director of the Liver Transplant Program. Dr. Ascher was recruited by the UCSF Department of Surgery and served as the Department Chair for 17 years.

Dr. Ascher is a fellow of the American College of Surgeons. She is a member of numerous other medical societies, including the Transplantation Society and the American Society of Transplant Surgeons, both of which she has served as President. She has also served on the Presidential Task Force on Organ Transplantation, Surgeon General's Task Force on Increasing Donor Organs, and Secretary of Health and Human Services Advisory Committee on Organ Transplantation. Dr. Ascher is currently a member of the WHO Taskforce on Donation and Transplantation of Human Organs and Tissues.



## STATE-OF-THE-ART SPEAKER

Martine Rothblatt, PhD



Chairman/CEO/Founder, United Therapeutics Corp

**PRESENTATION TITLE:** Creating the 1st Life-Saving Xenoheart Transplanted into a Person

*Thomas Starzl State-of-the-Art Lecture*

**Tuesday, June 7, 2022**

**11:45 am - 12:15 pm ET**

Martine Rothblatt is the Chairperson & CEO of United Therapeutics Corporation (UT). She started UT to save her youngest child's life from a rare illness after having previously created SiriusXM satellite radio and other satellite communications systems. She is also responsible for several innovations in aviation and architecture, including the design and piloting of an electric helicopter to Guinness World Records and creating the world's largest zero carbon footprint building. Her company is now saving hundreds of lives a year with medicines for pulmonary hypertension and neuroblastoma, and by restoring otherwise discarded donor lungs to transplantability.

United Therapeutics is also in pre-clinical development of manufactured kidneys, hearts and lungs to be delivered via autonomously flown electric vertical takeoff and landing (eVTOL) systems. Dr. Rothblatt led the efforts to create the first genetically-modified porcine hearts and kidneys transplanted into humans (xenotransplantation), resulting in a lifesaving xeno-heart transplant in January 2022.

Dr. Rothblatt earned her Ph.D. in Medical Ethics from the Royal London College of Medicine and Dentistry after earning JD and MBA degrees from UCLA, which also recently awarded her the UCLA Medal, its highest honor. She is an inventor on several patents and the author of several books, the most recent of which pertain to artificial cognition and cyber-consciousness.